Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Bayer AG
  6. News
  7. Summary
    BAYN   DE000BAY0017


Real-time Estimate Quote. Real-time Estimate Tradegate - 07/27 11:06:20 am
50.495 EUR   -1.70%
09:47aBAYER AG : JP Morgan reiterates its Buy rating
09:30aBlast in Germany industrial park kills one, four others missing
06:55aBAYER AG : Gets a Buy rating from Berenberg
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bayer : submits regulatory applications for oncology treatment combination of copanlisib and rituximab in the U.S. and EU

06/21/2021 | 08:05am EDT
Monday - June 21, 2021
Bitte JavaScript aktivieren / Please enable JavaScript

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. R&D expenses before special items amounted to 4.9 billion euros. For more information, go to www.bayer.com.

(1) ClinicalTrials.gov. Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas. Available online: https://clinicaltrials.gov/ct2/show/NCT01660451. Last Accessed: March 2021.
(2) Dreyling, M.; Santoro, A.; Mollica, L.; Leppa, S.; Follows, G.; Lenz, G.; Kim, W.S.; Nagler, A.; Dimou, M.; Demeter, J.; Ozcan, M.; Kosinova, M.; Bouabdallah, K.; Morschhauser, F.; Stevens, D.A.; Trevarthen, D.; Munoz, J.; Rodrigues, L.; Hiemeyer, F.; Miriyala, A.; Garcia-Vargas, J.; Childs, B.H.; Zinzani, P.L. Am. J. Hematol. 2020, 95, 362-371. Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.

Find more information at https://pharma.bayer.com
Follow us on Facebook: http://www.facebook.com/pharma.bayer
Follow us on Twitter: @BayerPharma

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conformthem to future events or developments.


Bayer AG published this content on 21 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 June 2021 12:04:08 UTC.

ę Publicnow 2021
All news about BAYER AG
09:47aBAYER AG : JP Morgan reiterates its Buy rating
09:30aBlast in Germany industrial park kills one, four others missing
06:55aBAYER AG : Gets a Buy rating from Berenberg
07/26PRESS RELEASE : BioNTech Provides Update on Plans to Develop Sustainable Solutio..
07/23PRESS RELEASE : Pfizer And BioNTech to Supply U.S. -2-
07/23Once its strength, water now threatens Germany
07/22SENSYNE HEALTH : Creates Chief Scientific Officer Post to Expand Ethical AI Rese..
07/21ADRs End Higher; BioNTech, AnPac Among Companies Actively Trading
07/21BAYER : Heart Failure Treatment Wins EU Market Authorization
07/21PRESS RELEASE : Tele Columbus AG: Broadband expansion kicks off in Leipzig
More news
Sales 2021 41 461 M 48 974 M 48 974 M
Net income 2021 3 600 M 4 253 M 4 253 M
Net Debt 2021 38 636 M 45 638 M 45 638 M
P/E ratio 2021 15,0x
Yield 2021 3,95%
Capitalization 50 467 M 59 604 M 59 613 M
EV / Sales 2021 2,15x
EV / Sales 2022 2,03x
Nbr of Employees 99 329
Free-Float 100,0%
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 51,37 €
Average target price 64,79 €
Spread / Average Target 26,1%
EPS Revisions
Managers and Directors
Werner Baumann Chairman-Management Board
Wolfgang U. Nickl Chief Financial Officer
Norbert Winkeljohann Chairman-Supervisory Board
Bijoy Sagar Chief Information Technology Officer
Paul Achleitner Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
BAYER AG6.68%59 604
JOHNSON & JOHNSON9.21%452 602
ROCHE HOLDING AG11.50%327 852
PFIZER, INC.13.58%234 040
NOVARTIS AG-0.17%221 954